東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Drug targets in cellular processes o...

Tuli, Hardeep Singh.

FindBook

Google Book

Amazon

博客來

Drug targets in cellular processes of cancer = from nonclinical to preclinical models /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Drug targets in cellular processes of cancer/ edited by Hardeep Singh Tuli.
其他題名:	from nonclinical to preclinical models /
其他作者:	Tuli, Hardeep Singh.
出版者:	Singapore :Springer Singapore : : 2020.,
面頁冊數:	xiii, 228 p. :ill. (some col.), digital ;24 cm.
內容註:	Chapter 1. History of oncotherapies in cancer biology -- Chapter 2. Electrochemical Sensors and Biosensors for the Detection of Cancer Biomarkers and Drugs -- Chapter 3. Cell cycle arrest: An impending therapeutic strategy to curb cancer -- Chapter 4. Apoptotic cell death: important cellular process as chemotherapeutic target -- Chapter 5. Regulatory roles of autophagy in cancer -- Chapter 6. ROS and Oxidative Stress in Cancer: Recent Advances -- Chapter 7. Inflammatory mediators: Potential drug targets in cancer -- Chapter 8. Pharmacologic modulation of the immune response against tumours in the elderly. Chapter 9. Angiogenesis: A Therapeutic Target for Cancer -- Chapter 10. Metastasis: A major driver of cancer pathogenesis -- Chapter 11. Designing Personalized and Innovative Novel Drug Therapies For Cancer Treatment.
Contained By:	Springer Nature eBook
標題:	Cancer - Molecular aspects. -
電子資源:	https://doi.org/10.1007/978-981-15-7586-0
ISBN:	9789811575860

Drug targets in cellular processes of cancer = from nonclinical to preclinical models /
Drug targets in cellular processes of cancerfrom nonclinical to preclinical models /[electronic resource] :edited by Hardeep Singh Tuli. - Singapore :Springer Singapore :2020. - xiii, 228 p. :ill. (some col.), digital ;24 cm.

Chapter 1. History of oncotherapies in cancer biology -- Chapter 2. Electrochemical Sensors and Biosensors for the Detection of Cancer Biomarkers and Drugs -- Chapter 3. Cell cycle arrest: An impending therapeutic strategy to curb cancer -- Chapter 4. Apoptotic cell death: important cellular process as chemotherapeutic target -- Chapter 5. Regulatory roles of autophagy in cancer -- Chapter 6. ROS and Oxidative Stress in Cancer: Recent Advances -- Chapter 7. Inflammatory mediators: Potential drug targets in cancer -- Chapter 8. Pharmacologic modulation of the immune response against tumours in the elderly. Chapter 9. Angiogenesis: A Therapeutic Target for Cancer -- Chapter 10. Metastasis: A major driver of cancer pathogenesis -- Chapter 11. Designing Personalized and Innovative Novel Drug Therapies For Cancer Treatment.

This book explores potential cellular drug targets for cancer therapy. The first couple of chapters describe conventional treatment (radiotherapy, chemotherapy, and immunotherapy) & detection (biosensors) strategies for cancer. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment. The book then discusses the regulation of various pro-apoptotic and anti-apoptotic proteins via chemotherapeutic drugs. In addition, it examines the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells. It subsequently reviews the role of reactive oxygen (ROS) species during carcinogenesis and during chemotherapy, and the potential of anti-inflammatory routes for the development of new therapeutic modulators. Lastly, it describes therapeutic strategies that target the tumor microenvironment and various angiogenic pathways for the treatment of cancer and to develop personalized medicine. Given its scope, the book is valuable resource for oncologists, cancer researchers, clinicians, and pharmaceutical industry personnel.

ISBN: 9789811575860

Standard No.: 10.1007/978-981-15-7586-0doiSubjects--Topical Terms:

661419
Cancer
--Molecular aspects.

LC Class. No.: RC268.4

Dewey Class. No.: 616.994

Drug targets in cellular processes of cancer = from nonclinical to preclinical models /
LDR:03061nmm a2200325 a 4500 001 2243426
003 DE-He213
005 20201231093351.0
006 m d
007 cr nn 008maaau
008 211207s2020 si s 0 eng d
020 $a 9789811575860 $q (electronic bk.)
020 $a 9789811575853 $q (paper)
024 7 $a 10.1007/978-981-15-7586-0 $2 doi
035 $a 978-981-15-7586-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC268.4
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
090 $a RC268.4 $b .D794 2020
245 0 0 $a Drug targets in cellular processes of cancer $h [electronic resource] : $b from nonclinical to preclinical models / $c edited by Hardeep Singh Tuli.
260 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2020.
300 $a xiii, 228 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Chapter 1. History of oncotherapies in cancer biology -- Chapter 2. Electrochemical Sensors and Biosensors for the Detection of Cancer Biomarkers and Drugs -- Chapter 3. Cell cycle arrest: An impending therapeutic strategy to curb cancer -- Chapter 4. Apoptotic cell death: important cellular process as chemotherapeutic target -- Chapter 5. Regulatory roles of autophagy in cancer -- Chapter 6. ROS and Oxidative Stress in Cancer: Recent Advances -- Chapter 7. Inflammatory mediators: Potential drug targets in cancer -- Chapter 8. Pharmacologic modulation of the immune response against tumours in the elderly. Chapter 9. Angiogenesis: A Therapeutic Target for Cancer -- Chapter 10. Metastasis: A major driver of cancer pathogenesis -- Chapter 11. Designing Personalized and Innovative Novel Drug Therapies For Cancer Treatment.
520 $a This book explores potential cellular drug targets for cancer therapy. The first couple of chapters describe conventional treatment (radiotherapy, chemotherapy, and immunotherapy) & detection (biosensors) strategies for cancer. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment. The book then discusses the regulation of various pro-apoptotic and anti-apoptotic proteins via chemotherapeutic drugs. In addition, it examines the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells. It subsequently reviews the role of reactive oxygen (ROS) species during carcinogenesis and during chemotherapy, and the potential of anti-inflammatory routes for the development of new therapeutic modulators. Lastly, it describes therapeutic strategies that target the tumor microenvironment and various angiogenic pathways for the treatment of cancer and to develop personalized medicine. Given its scope, the book is valuable resource for oncologists, cancer researchers, clinicians, and pharmaceutical industry personnel.
650 0 $a Cancer $x Molecular aspects. $3 661419
650 0 $a Drug targeting. $3 768297
650 0 $a Cancer $x Chemotherapy. $3 753516
650 0 $a Cancer $x Research. $3 696466
650 0 $a Immunology. $3 611031
650 0 $a Cytology. $3 516274
650 1 4 $a Cancer Research. $3 891172
650 2 4 $a Cell Biology. $3 892383
700 1 $a Tuli, Hardeep Singh. $3 3503469
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-981-15-7586-0
950 $a Biomedical and Life Sciences (SpringerNature-11642)